**Alto Neuroscience, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update**
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company, has released its financial results for the fiscal year ended December 31, 2025. The company reported a net loss of $63.2 million, compared to a net loss of $61.4 million for the previous fiscal year. Research and development expenses totaled $45.6 million, a slight decrease from $47.0 million in 2024, primarily due to the completion of certain clinical trials and timing of enrollment in ongoing trials, offset by increased development work on ALTO-207 and ALTO-101. General and administrative expenses decreased to $20.7 million from $21.6 million in the prior year, mainly due to reduced consulting and professional fees.
The company highlighted key operational developments, including the acquisition of ALTO-207 and ALTO-208 from Chase Therapeutics Corporation in May 2025. Alto also completed an exploratory Phase 2 proof-of-concept trial of ALTO-203 in MDD, identifying a patient selection biomarker and positive pharmacodynamic results. Furthermore, the FDA granted Fast Track designation to ALTO-101 for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). In February 2025, Alto announced a favorable outcome from the planned interim analysis for the Phase 2b trial of ALTO-300 as an adjunctive treatment for patients with MDD, resulting in a recommendation to continue the study with an increased target biomarker positive population.
Alto Neuroscience's financial position includes $177.0 million in cash, cash equivalents, and restricted cash as of December 31, 2025. The company believes these resources will be sufficient to fund operating expenses and capital expenditure requirements into 2028, taking into account anticipated proceeds under the Convertible Grant Agreement with The Wellcome Trust Limited. The company's future success is contingent upon the successful development and commercialization of its product candidates, which are subject to regulatory approvals and market acceptance.
Looking ahead, Alto Neuroscience plans to initiate a Phase 2b trial of ALTO-207 in the first half of 2026 and a Phase 3 trial by early 2027, pending FDA feedback. Topline data from the Phase 2b trial of ALTO-300 is expected in mid-2026, and topline data from the Phase 2 trial of ALTO-101 is anticipated around the end of the first quarter of 2026. The company will continue to evaluate the best indication to pursue with ALTO-203 and expects to provide further details on planned development in the future. These forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on precision psychiatry. It develops personalized treatments for neuropsychiatric disorders such as major depressive disorder, bipolar depression, and schizophrenia using its proprietary Precision Psychiatry Platform. The platform integrates neurobiological data and machine learning to identify biomarkers for targeted patient populations. Alto’s pipeline includes novel small molecules and repurposed drugs designed to improve treatment efficacy and patient outcomes in CNS disorders.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.